Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019

Biogen logo with Healthcare background
Image from MarketBeat Media, LLC.

Biogen NASDAQ: BIIB expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference.

Alaimo said Biogen would analyze both trials of litifilimab before releasing the results, which Jefferies Senior Biotech Analyst Andrew Tsai said were expected in early December. A conference call was possible but not standard practice, she said. Results from a trial in cutaneous lupus erythematosus, or CLE, are expected early next year, according to Alaimo.

“We have plans for every single scenario,” Alaimo said of commercial preparations for the lupus program. She added that the company would post jobs but would not commit launch spending until it had results from all three trials.

Growth outlook and product launches

Alaimo described Biogen as being at a turnaround point following approximately four years of cost reductions, capital reallocation, operational changes and pipeline reprioritization. She said the company wants to grow revenue next year, which would mark its first annual growth since 2019.

Among products she highlighted were Alzheimer’s treatment Leqembi, postpartum depression treatment Zurzuvae, and Syfovre and Empaveli, which came to Biogen through the Apellis transaction.

Alaimo said the company expects quarter-over-quarter growth for Leqembi. She pointed to early use of the at-home subcutaneous option Iqlik by physicians who had not previously prescribed Leqembi or rival Kisunla, as well as switches from Kisunla. Some patients have also moved from intravenous Leqembi to Iqlik, though some subsequently switched back, she said.

For Empaveli, Alaimo said Biogen identified weakness in its paroxysmal nocturnal hemoglobinuria business after the Apellis transaction and had returned that portion to growth. She also said she expects Syfovre to grow, citing commercial changes and opportunities to address issues in geographic atrophy.

Lupus launch plans depend on data

Alaimo said any filing decision for litifilimab would depend on the trial results. Systemic lupus erythematosus, or SLE, and CLE follow different regulatory paths, she said, adding that the company wanted approval as quickly as possible.

She said physicians and patients want treatments that work quickly without concerns about infection risk, alongside insurance coverage. Existing products face challenges that include slow onset, modest efficacy or concerns about infection risk, she said.

Alaimo estimated that the SLE and CLE markets could each potentially reach $6 billion to $8 billion. She put the patient populations at approximately 300,000 for SLE and 250,000 for CLE, including 50,000 people with both conditions.

Biogen is also developing dapirolizumab pegol for SLE with UCB. If both lupus drugs succeed, Alaimo said, Biogen would build separate teams for them, subject to the data and regulatory approval. Tsai said Phase 3 data for dapirolizumab pegol is expected in 2028.

Felzartamab and spinal muscular atrophy

Alaimo said Biogen is aware of approximately 11,000 diagnosed U.S. patients with antibody-mediated rejection, or AMR, an indication being studied for felzartamab. The company is working to determine where those patients are and how quickly they could reach transplant centers. Some have already lost their transplanted kidney and are not the target patients, she said.

She said Biogen’s experience with Empaveli gives it access to general nephrologists who care for transplant patients, while a relatively small team could reach transplant physicians. Tsai said Phase 3 AMR data is expected in the first half of next year.

In spinal muscular atrophy, Alaimo said higher-dose Spinraza had helped Biogen retain patients and prevent discontinuations. She said the company is studying salanersen across several treatment settings and believes its proposed annual dosing could attract patients. Tsai said Phase 3 data for salanersen is expected in 2028.

About Biogen (NASDAQ:BIIB)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biogen Right Now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines